Alvotech (OISE:ALVO) Retained Earnings: kr-301,963 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OISE:ALVO Alvotech OISE:ALVO
54 GF Score
Price kr424.00
GF Value kr2,327.40
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Alvotech Retained Earnings?

Alvotech OISE:ALVO +0.71% 54 Retained Earnings is kr-301,963 Mil as of Mar. 2026. GuruFocus rates OISE:ALVO with a GF Score™ of 54/100 and a GF Value™ of kr2,327.40 (Possible Value Trap). The stock has 7 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Alvotech's retained earnings for the quarter that ended in Mar. 2026 was kr-301,963 Mil.

Alvotech's quarterly retained earnings declined from Sep. 2025 (kr-288,485 Mil) to Dec. 2025 (kr-302,092 Mil) but then increased from Dec. 2025 (kr-302,092 Mil) to Mar. 2026 (kr-301,963 Mil).

Alvotech's annual retained earnings declined from Dec. 2023 (kr-276,526 Mil) to Dec. 2024 (kr-305,592 Mil) but then increased from Dec. 2024 (kr-305,592 Mil) to Dec. 2025 (kr-302,092 Mil).


Alvotech  (OISE:ALVO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Alvotech Retained Earnings Historical Data

* Premium members only.

The historical data trend for Alvotech's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alvotech Retained Earnings Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -142,977.84 -207,360.46 -276,525.70 -305,592.27 -302,092.33

Alvotech Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -291,842.74 -287,826.44 -288,484.83 -302,092.33 -301,963.21
OISE:ALVO
54GF Score
Alvotech OISE:ALVO
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alvotech Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of kr-301,963 Mil mean?
Alvotech (OISE:ALVO) has a Retained Earnings of kr-301,963 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Alvotech and its competitors.
Is Alvotech's Retained Earnings too high?
Alvotech's current Retained Earnings is kr-301,963 Mil. Overall, Alvotech has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Retained Earnings compare to PAHC and COLL?
Alvotech's Retained Earnings of kr-301,963 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Alvotech and its competitors. Alvotech's current Retained Earnings is kr-301,963 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (OISE:ALVO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2,327.40, compared to a current price of kr424.00 — trading 81.8% below its estimated fair value. The current Retained Earnings is kr-301,963 Mil. Alvotech's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Alvotech (OISE:ALVO), the current Retained Earnings is kr-301,963 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alvotech (OISE:ALVO) Overvalued in 2026?

Based on GuruFocus' analysis, Alvotech stock appears to be undervalued. The current stock price of kr424.00 is trading 81.8% below its estimated GF Value™ of kr2,327.40. GuruFocus considers Alvotech to be Possible Value Trap.

Key valuation signals for OISE:ALVO:

  • Retained Earnings: kr-301,963 Mil
  • GF Value™: kr2,327.40 vs. price of kr424.00 (81.8% below fair value)
  • GF Score™: 54/100 with 7 warning signs

No single metric tells the full story. See the OISE:ALVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alvotech Business Description

Other Exchanges ALVO:USAZ45:Germany
Address 9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
54GF Score

Get the complete analysis for OISE:ALVO

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr424.00
Price
kr2,327.40
GF Value